Schellenberg Lab retweeted
#PhF25 predoc awardee Anh Cong @MayoGradSchool is researching how to protect the heart during #chemotherapy. She's studying the proteins targeted by anthracyclines, which are effective against #cancer but can cause heart issues.
Watch the full interview: phrmafoundation.org/news-eve…
This was an awesome collaborative team effort by scientists from @MayoClinic @mayoclinicbmb @MayoGradSchool @MayoCancerCare @newcastleuni and the faculties of Pharmacy and Medicine at Charles University.
Topobexin is an inhibitor that targets Topoisomerase IIβ's ATPase domain—protecting the heart from anthracycline chemo damage without reducing anticancer power. Read our article about this potentially game-changer in cardio-oncology @natcomms.nature.com rdcu.be/en4ak.
Schellenberg Lab retweeted
Endoxifen is known to be a more potent inhibitor of ER alpha compared to tamoxifen. Based on an unbiased proteomic screen, we identify protein kinase beta as a new endoxifen drug target, resulting in suppression of AKT signaling and apoptosis
pubmed.ncbi.nlm.nih.gov/3811…


